National Institute of Allergy and Infectious Diseases (NIAID)

NIAID’s approach to autoimmune disease research has the potential to improve understanding and lead to treatments for many different autoimmune diseases. The studies we support seek to understand how the immune system contributes to autoimmunity, to develop better diagnostic tools and animal models of autoimmune disease, and to identify effective treatment and prevention strategies. This strategy has led to the identification of specific immune cells and molecular pathways involved in autoimmune disease, and consequently, to new treatment targets. Learn more: https://go.nih.gov/RDBftx1 #AutoimmuneAwarenessMonth #autoimmunity #autoimmune #research #PublicHealth #NIH #NIAID

Looking for resources to support your #autoimmune disease research? Visit our Resources for Researchers webpage to find information about available resources like de-identified data and samples. Learn more at https://go.nih.gov/ShnI8x9 #AutoimmuneAwareness #ResearchResources #NIAID

NIAID supports a broad range of basic and clinical #research on autoimmunity. Knowledge gained from basic research helps inform new experimental methods of diagnosis, prevention, and treatment for #autoimmune diseases such as lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel diseases, and more. Learn more about autoimmune disease research: https://go.nih.gov/uqdDtwj   #AutoimmuneAwarenessMonth #AutoimmuneResearch #PublicHealth #NIAID 

Licensing Opportunity: Human Monoclonal Antibodies That Target Blood-Stage RH5 for Malaria Control Commercially available antibodies that target Plasmodium falciparum—the parasite responsible for most cases of malaria in humans—are primarily directed against the circumsporozoite protein (CSP). While CSP is present prior to blood-stage infection, antibodies specific to proteins in the blood stage may aid in preventing and controlling parasitic infection. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have developed 25 human monoclonal antibodies that target the RH5 complex, an essential antigen present in the blood stage. In vitro experiments demonstrated potent activity for these antibodies, which may be used alone or in combination with existing antibodies. To learn more about this collaboration opportunity, visit https://lnkd.in/ejrxT9t5 or contact Dawn Taylor-Mulneix at dawn.taylor-mulneix@nih.gov and reference E-014-2023. #Malaria #Parasite #NIAID #Antibodies #NIAIDTechTransfer  

📢 NIH BioArt Source, a free science and biomedical art resource library, was created by professional medical illustrators and offers an array of high-quality illustrations, vectors, and brushes, free to use and download. See the full catalog of free science and biomedical illustrations and more information on this tool at https://lnkd.in/eyFrrWA6 #ScienceIllustration #FreeResource #MedicalArt

Metadata plays a crucial role in sharing and reusing scientific data. Understanding metadata can accelerate your research, increase the visibility of your work, and advance the field of infectious and immune-mediated disease research. Learn about using metadata in this #NIAIDDataScience Dispatch: https://go.nih.gov/w7oRPk0 Photo Credit: National Eye Institute, National Institutes of Health

Follow this thread for the final update about #NIAID-supported research from #CROI2025. For full text abstracts, please visit: https://lnkd.in/eZQ_DndM 1. An analysis from an international study characterized the response to integrase strand transfer inhibitor-based #AntiretroviralTherapy after acquiring HIV while taking long-acting cabotegravir for #HIV pre-exposure prophylaxis: https://lnkd.in/exW9Pq_p 2. The early start of #HIV #AntiretroviralTherapy had no effect on cardiovascular disease (CVD) risk in people with HIV who were at low risk of CVD & had relatively high viral suppression before the study: https://lnkd.in/eWvH7nDu 3. #HIV was detected in the spinal fluid cells of men with HIV who had been taking #AntiretroviralTherapy for up to 2 decades: https://lnkd.in/eFuGjnwK 4. A study showed for the first time the presence of mutations on a certain part of the #HIV virus in people who were taking a common #AntiretroviralTherapy regimen & who had unsuppressed viral replication: https://lnkd.in/ehNYg9br 5. An analysis from an international study of people with #HIV identified factors associated with benefitting from a reduced risk of major adverse cardiovascular events while taking a statin: https://lnkd.in/eVx3bZie 6. An analysis from an international study found that higher levels of frailty were associated with an increased risk of major adverse cardiovascular events in people with #HIV: https://lnkd.in/eanhMdzG 7. An analysis from an international study of people with #HIV found that switching to an integrase strand transfer inhibitor-based #AntiretroviralTherapy regimen increased the risk of weight gain & cardiometabolic complications over the next five years: https://lnkd.in/eCHF8QTa 8. A study found no evidence of brain atrophy in young adults who initiated #AntiretroviralTherapy soon after acquiring #HIV: https://lnkd.in/e_8WaXwM 9. Some people with HIV who acquired SARS-CoV-2 experienced structural brain changes that were not detected in a cohort before the COVID-19 pandemic, based on an exploratory analysis from an #HIV treatment study that included periodic brain MRIs: https://lnkd.in/ejTVzKy4 10. A novel group of therapeutic #HIV vaccines was safe & induced an immune response in people with HIV on #AntiretroviralTherapy, inducing stronger responses in younger people: https://lnkd.in/eBNucy67 11. Monitoring levels of #HIV pre-exposure prophylaxis (#PrEP) drugs in the urine of pregnant & postpartum women helped them take PrEP at its prescribed frequency: https://lnkd.in/eG5FJmg4 12. Among people with #HIV in several African countries, a monovalent COVID-19 vaccine booster was as effective at protecting against symptomatic COVID-19 as a newer, bivalent booster: https://lnkd.in/e3pTYzWq

An NIH-sponsored clinical trial of a vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore. Lassa fever is a viral hemorrhagic disease that can be fatal and that causes permanent hearing loss in up to one-third of those who contract it. The candidate vaccine was developed by NIH-supported researchers at Thomas Jefferson University. Learn more at https://go.nih.gov/8Z14dB2

Topical steroid withdrawal (TSW) results in dermatitis that is distinct from eczema and is caused by an excess of an essential chemical compound in the body, according to a new study from researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). Scientists identified treatments that could be studied in clinical trials for the condition based on their potential to lower levels of the chemical compound—called nicotinamide adenine dinucleotide (NAD+), a form of vitamin B3. The findings were published today in the Journal of Investigative Dermatology. Learn more at: https://go.nih.gov/eulULoc #TopicalSteroidWithdrawal #TSW #Eczema #NIAID

Follow this thread for the second update about #NIAID-supported research from #CROI2025. For full text abstracts, please visit the conference website: https://lnkd.in/eZQ_DndM 1. People with #HIV whose alcohol consumption was defined as at-risk by a common screening tool reported lower consumption after taking the diabetes drug semaglutide. Learn more: https://lnkd.in/erWgD6fb 2. An analysis identified risk factors for osteonecrosis, a condition caused by a limited blood supply to bone tissue that results in bone damage, in people with #HIV as they age. Learn more: https://lnkd.in/eTgz9jv7 3. A study identified an association between higher levels of an inflammatory disease-causing enzyme and chronic obstructive pulmonary disease in people with #HIV. Learn more: https://lnkd.in/ew5VtwXM 4. A data analysis identified a strong association between housing instability and aging among people with #HIV, including younger and virally suppressed groups. Learn more: https://lnkd.in/ejmZ2fTz 5. An analysis from a cohort of more than 15,000 people with HIV showed gaps in the rollout of the long-acting #HIV drugs cabotegravir and rilpivirine. Learn more: https://lnkd.in/evizsXb7 6. Findings from a U.S. cohort study showed that the use of substances like methamphetamine was associated with lower rates of viral suppression in people with #HIV. Learn more: https://lnkd.in/e4YuBzCd 7. An analysis from a cohort of more than 6,000 people with #HIV found an association between frailty and death, including in those under 50 years of age. Learn more: https://lnkd.in/e4YuBzCd 8. Researchers found that DNA profiling helped address inconsistent HIV test results in a person who had previously used long-acting injectable cabotegravir for #HIV pre-exposure prophylaxis. Learn more: https://lnkd.in/eu9fz-DA 9. High rates of sexually transmitted infections like #syphilis, #gonorrhea, & trichomonas were detected in women participating in a clinical trial of long-acting #HIV pre-exposure prophylaxis. Learn more: https://lnkd.in/ewTEQcbd 10. Single isolated laboratory tests failed to accurately confirm the #HIV status of women who had recently received long-acting injectable cabotegravir for HIV pre-exposure prophylaxis. Learn more: https://lnkd.in/ejMih3b8 11. A randomized controlled trial examined a mobile health service strategy combining #HIV prevention and treatment with addiction care and other services for people who inject drugs. Learn more: https://lnkd.in/ewWkU-gN